GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

About this update from Goodrx Holdings, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":389,"url":"https://media.zenfs.com/en/business-wire.com/70991987eaec4dc718c174f27c886f4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3BdeKCH4NXvfkqe3BxCveQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTc3OA--/https://media.zenfs.com/en/business-wire.com/70991987eaec4dc718c174f27c886f4a","width":480,"height":389}},"lazy":false},{"type":"text","content":"Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"Brief Summary:","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month","length":86,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Available at GoodRx’s nationwide pharmacy network","length":49,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adds an oral option to the Ozempic treatment portfolio","length":54,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":189,"olType":false},{"type":"text","content":"SANTA MONICA, Calif., May 01, 2026--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk’s Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide.","length":375,"tagName":"p"},{"type":"text","content":""As Novo Nordisk brings the Ozempic pill to market, we’re focused on helping patients access it with clear, transparent pricing," said Wendy Barnes, President & CEO of GoodRx. "The availability of an oral formulation under the Ozempic brand marks an important step forward, offering a convenient alternative to the established injectable. It also reflects GoodRx’s expanding work with Novo Nordisk across the entire semaglutide portfolio and its role in supporting patient access."","length":505,"tagName":"p"},{"type":"text","content":""We’re excited to bring the Ozempic pill to the GoodRx platform – adding a newly approved oral option under a brand people know and ...

More updates from Goodrx Holdings, Inc.